CClinicalTrials.gg
CompletedNCT04038632Updated Mar 26, 2025

Impact of an Innovative Childhood TB Diagnostic Approach Decentralized to District Hospital and Primary Health Care Levels on Childhood Tuberculosis Case Detection and Management in High Tuberculosis Incidence Countries (TB-Speed Decentralisation)

An interventional study of Decentralization of Childhood TB Diagnosis in Tuberculosis in Children, sponsored by Institut National de la Santé Et de la Recherche Médicale, France. Completed at 59 sites in 6 countries. Open to participants aged Up to 14 Years. Per ClinicalTrials.gov, last updated 2025-03-26.

Sponsored by Institut National de la Santé Et de la Recherche Médicale, France · Not applicable, Interventional, and Diagnostic

Phase
Not applicable
Study type
Interventional
Enrollment
3,106
Allocation
Randomized
Ages
Up to 14 Years
Sex
All
01

Study summary

The TB-Speed Decentralisation study aims to increase childhood Tuberculosis (TB) case detection at district hospital (DH) and Primary health Care (PHC) levels using adapted and child-friendly specimen collection methods, i.e. Nasopharyngeal Aspirate (NPA) and stool samples, sensitive microbiological detection tests (Ultra) close to the point-of-care (Omni/G1(Edge)), reinforced training on clinical diagnosis, and standardized CXR quality and interpretation using digital radiography.

The TB-Speed Decentralisation study will evaluate the impact of an innovative patient care level diagnostic approach deployed at DH and PHC levels, namely the DH focused and the PHC focused decentralization strategies. This is aimed at, improving case detection in 6 high TB incidence in low/moderate resource countries: Cambodia, Cameroon, Côte d'Ivoire, Mozambique, Sierra Leone, and Uganda, and compare effectiveness and cost-effectiveness of the two different decentralization approaches.

The hypothesis is that, in countries with high and very high TB incidence (100-299 and ≥300 cases/100,000 population/year, respectively), a systematic approach to the screening for and diagnosis of TB in sick children presenting to the health system will increase childhood TB case detection, especially PTB, which represents the majority of the disease burden (>75% of case). The study also hypothesizes that sputum collection using battery-operated suction machines and microbiological TB diagnosis using Omni/G1 (Edge) can be decentralized to PHC level, thus enabling TB diagnosis and treatment in children at PHC level.

Read the detailed description

This will be an operational research study using:

  • a before and after cross-sectional design to assess the impact of decentralizing an innovative childhood TB diagnostic approach
  • a cross-sectional and nested cohort design to compare two different decentralization strategies at DH and PHC levels.
  • quantitative and qualitative methods The intervention will be at two levels: at patient care level where an innovative childhood TB diagnostic approach will be implemented, and at health systems level where two distinct decentralization strategies will be implemented. The patient care level TB diagnostic approach consists of systematic TB screening, clinical evaluation, NPA and stool or sputum testing using Xpert Ultra, and optimised CXR reading. The two decentralization strategies are the DH-focused and the PHC-focused implementation of the innovative childhood TB diagnostic approach. Two districts per participating countries will be randomly assigned to implement the DH or PHC-focused strategies.

The study will also include a nested cohort at both the DH and PHC during the intervention phase for a selected sub-set of children with presumptive TB and all children with a diagnosis of TB that consent to participate. This prospective cohort will enable to further document study endpoints related to follow up (TB treatment outcome) and to document TB diagnosis by assessing spontaneous resolution or resolution under TB treatment.

The study will comprise an observation phase followed by an intervention phase in participating districts. During the last month of the observation phase, each district will be randomly assigned to implement either DH or PHC-focused decentralisation. There will be no patient level randomisation.

During this 3-month observation phase, the study will 1) describe the childhood TB diagnosis data and practices; 2) describe the referral processes and outcomes of referrals for TB diagnosis and treatment where feasible and 3) assess existing challenges in childhood TB diagnosis and treatment, as well as readiness (including potential challenges) for the study intervention implementation. There will be no interference with the routine TB childhood diagnosis processes.

Mixed-methods (quantitative and qualitative) will be used including the collection of retrospective and prospective aggregated data by study nurses from facility registers, the implementation of a self-administered questionnaire among all healthcare workers (HCWs), the observation of consultations and care provided, and the conduct of individual interviews with HCWs and key informants.

At the beginning of the intervention phase, a 3-months preparation period will set up the health facilities for decentralization by providing equipment, materials, and reagents, training health workers in childhood TB care, in NPA and stool collection and testing on Ultra, setting up G1 (Edge) at PHC or G4 at DH if not already available and digital CXR and CXR quality control. Existing health care workers will be trained in childhood TB care according to the National Tuberculosis Program (NTP) guidelines, and also in NPA and stool collection and testing on Ultra for study purposes.

Implementation of the innovative childhood TB diagnostic approach at the selected DH and PHC will start as soon as sites are equipped and HCWs trained in childhood TB care and NPA and stool collection, and will implement continued capacity building at sites, regular clinical mentoring visits with NTP or their representative, and continued CXR quality control.

The 6-month prospective cohort follow-up study will be initiated immediately and will consecutively include every tenth child with presumptive TB and all children diagnosed with TB.

Individual data collection will be initiated as soon as the innovative childhood TB diagnostic approach including NPA and stool sample collection and Ultra testing is implemented in the site and will be conducted throughout the intervention phase to document secondary endpoints. Aggregated data for TB screening will be collected throughout the study.

Feasibility, acceptability, and compliance to the intervention protocol will be assessed by mixed methods including a repeat self-administered questionnaire among all HCWs, observations of consultations and care provided, and individual interviews with HCWs, National TB program \& local health authorities representatives, and beneficiaries. i.e. parents/guardians.

02

Conditions studied

  • Tuberculosis in Children

Browse trials for

Keywords

  • Decentralized Diagnosis approaches
  • Childhood TB
  • Case detection
03

Who can participate

Ages eligible
Up to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Sick children seeking care at Oupatient Department of District Hospital or Primary Health Center
  • Age \<15 years

Exclusion criteria

Exclusion Criteria:

  • None
04

Study design

Phase
Not applicable
Primary purpose
Diagnostic
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
3,106 participants (actual)

Study arms

  • Experimental
    District Hospital focused decentralization strategy

    In this strategy, the patient care level innovative childhood TB diagnostic approach will be implemented at the DH level. PHCs in this district, will only conduct systematic TB screening.

    Other: Decentralization of Childhood TB Diagnosis

  • Experimental
    Primary Health Center focused decentralization strategy

    In this strategy, the patient care level innovative childhood TB diagnostic approach will be done at the PHC.

    Other: Decentralization of Childhood TB Diagnosis

Interventions

  • OtherDecentralization of Childhood TB Diagnosis

    The patient care level TB diagnostic approach consists of systematic TB screening, clinical evaluation, NPA and stool or sputum testing using Xpert Ultra, and optimised CXR reading will be implemented at DH and PHC levels

05

What researchers measure

Primary outcomes

  1. Children diagnosed with TB

    Proportion of TB cases detected among sick children routinely attending outpatient services before and after the intervention

    Time frame: Day 0

Secondary outcomes

  1. TB case detection

    Proportion of TB cases (confirmed and unconfirmed) detected among children identified as presumptive TB

    Time frame: Month 6

  2. TB screening in outpatient children - 1

    Proportion of children screened for TB among sick children attending outpatient services

    Time frame: Day 7

  3. TB screening in outpatient children - 2

    Proportion of children identified with presumptive TB among children screened

    Time frame: Day 7

  4. Feasibility of implementing the different diagnostic approach components - 1

    Proportion of children with presumptive TB enrolled in the study receiving the different components of the innovative childhood TB diagnostic approach (NPA and stool or sputum sampling attempt and success, sample testing with Ultra and results, clinical evaluation, CXR and interpretation, full diagnostic package)

    Time frame: Day 7

  5. Feasibility of implementing the different diagnostic approach components - 2

    Time to sample test and results delivery to clinician

    Time frame: Day 7

  6. Feasibility of implementing the different diagnostic approach components - 3

    Number of visits to the health facility until final diagnosis

    Time frame: Day 7

  7. TB treatment uptake and time to TB treatment initiation - 1

    Proportion of children initiating TB treatment among those diagnosed as TB

    Time frame: Month 6

  8. TB treatment uptake and time to TB treatment initiation - 2

    Time from positive TB screening to TB treatment initiation

    Time frame: Month 6

  9. Cost-effectiveness from the health services perspective

    Incremental-Cost Effectiveness Ratio (ICER) of the diagnostic approach

    Time frame: Month 22

  10. Acceptability by health care providers, NTPs and health authorities, and beneficiaries

    Perceptions and experience of the intervention by healthcare workers (HCWs), the NTP and health authorities, and the beneficiaries (parents/guardians)

    Time frame: Day 0

  11. Fidelity of the implementation of the diagnostic approach as compared to the protocol and study procedures - 1

    Changes in the intervention implementation as compared to 1) study standard implementation procedures and 2) country implementation procedures. These changes could be related to NTP guidelines dispositions, adaptation to local context and constraints not initially planned per standard and country implementation procedures

    Time frame: Month 6

  12. Fidelity of the implementation of the diagnostic approach as compared to the protocol and study procedures - 2

    Proportion of clinical mentoring visits performed per study procedures; proportion of health facilities implementing NPA and stool sample collection and performing sample processing and Ultra testing per study procedures

    Time frame: Month 22

  13. Performance of the diagnostic approach at patient level

    Sensitivity and specificity of the diagnostic approach as compared to the reference diagnosis based on the Case Definitions for Classification of Intrathoracic Tuberculosis in Children for clinical research

    Time frame: Month 6

  14. TB treatment outcome

    TB treatment outcome as defined by WHO

    Time frame: Month 6

  15. Diagnostic performance of CXR reading by clinicians at DH and PHC levels

    Sensitivity and specificity of CXR reading by clinicians at DH and PHC to detect lesions suggestive of TB as compared to the reference reading (independent reading by external radiologist experts)

    Time frame: Month 6

  16. Added value of CXR in the diagnosis of TB in children as compared to microbiology and clinical evaluation only

    Proportion of children diagnosed with TB based on CXR and incremental yield of TB detection with CXR results as compared to microbiological (Ultra on NPA and stool or sputum) and clinical evaluation, respectively

    Time frame: Month 6

  17. Uptake of the quality control of the CXR reading

    Proportion of CXR selected for quality review assessed by the reference reviewer and time to results of the quality control to the clinic

    Time frame: Month 6

06

Study locations

59 sites
  • Angroka Rh
    Angroka, Cambodia
  • Taphem Hc
    Angroka, Cambodia
  • Tropang Andert Hc
    Angroka, Cambodia
  • Batheay Rh
    Batheay, Cambodia
  • Choeung Chnok Hc
    Batheay, Cambodia
  • Tumnub Hc
    Batheay, Cambodia
  • KUS HC
    KUS, Cambodia
  • Nhaeng Nhang Hc
    Nhaeng Nhang, Cambodia
  • Phaav HC
    Phaav, Cambodia
  • Sambour Hc
    Sambour, Cambodia
  • Csi Messngssang
    Bafia, Cameroon
  • HD BAFIA
    Bafia, Cameroon
  • Csi Balamba Bafia
    Balamba, Cameroon
  • Cma Batchenga
    Batchenga, Cameroon
  • Cma Bokito Bafia
    Bokito, Cameroon
  • Csi Essong
    Essong, Cameroon
  • Cma Kiiki Bafia
    Kiiki, Cameroon
  • Cma Fomakap
    Obala, Cameroon
  • Csi Ngogo
    Obala, Cameroon
  • Obala Hosp
    Obala, Cameroon
  • Dr Banteapleu
    Banteapleu, Côte D'Ivoire
  • Csu Dakpadou
    Dakpadou, Côte D'Ivoire
  • Csr Daleu
    Daleu, Côte D'Ivoire
  • H G de Danane
    Danane, Côte D'Ivoire
  • Csu Kouan-Houle
    Kouan-houle, Côte D'Ivoire
  • Csu Mahapleu
    Mahapleu, Côte D'Ivoire
  • Csr Medon
    Medon, Côte D'Ivoire
  • CMS SAGO
    Sago, Côte D'Ivoire
  • Dr de Sahoua
    Sahoua, Côte D'Ivoire
  • H G Sassandra
    Sassandra, Côte D'Ivoire
  • Chiaquelane
    Chiaquelane, Mozambique
  • Chibonzane
    Chibonzane, Mozambique
  • Chidenguele
    Chidenguele, Mozambique
  • Chalocuane
    Chokwe, Mozambique
  • HOKWE
    Chokwe, Mozambique
  • Hosp Rural Chokwe
    Chokwe, Mozambique
  • MACUACUA
    Macuacua, Mozambique
  • Hospital Rural de Manjacaze
    Manjacaze, Mozambique
  • Laranjeira
    Manjacaze, Mozambique
  • Babara Chc
    Babara, Sierra Leone
  • Bo Govt Hosp
    BO, Sierra Leone
  • New Police barracks
    BO, Sierra Leone
  • Gbinti Chc
    Gbinti, Sierra Leone
  • Gerihun Chc
    Gerihun, Sierra Leone
  • Koribondo Chc
    Koribondo, Sierra Leone
  • Mange Chc
    Mange, Sierra Leone
  • Njala University Chc
    Njala, Sierra Leone
  • Petifu Chc
    Petifu, Sierra Leone
  • Port Loko Govt Hosp
    Port Loko, Sierra Leone
  • Buyamba Hc Iii
    Buyamba, Uganda
  • Kambuga Hospital
    Kambuga, Uganda
  • Kanungu Hciv
    Kanungu, Uganda
  • Kanyantorogo Hciii
    Kanyantorogo, Uganda
  • Lwamaggwa Hc Iii
    Lwamaggwa, Uganda
  • Lwanda Hc Iii
    Lwanda, Uganda
  • St Bernards Manya Hc Iii
    Manya, Uganda
  • Matanda Hciii
    Matanda, Uganda
  • Nyamirama HC III
    Nyamirama, Uganda
  • Rakai Hospital
    Rakai, Uganda
07

References and documents

Publications

  • Joshi B, De Lima YV, Massom DM, Kaing S, Banga MF, Kamara ET, Sesay S, Borand L, Taguebue JV, Moh R, Khosa C, Breton G, Mwanga-Amumpaire J, Bonnet M, Wobudeya E, Marcy O, Orne-Gliemann J; TB-Speed Decentralization study group. Acceptability of decentralizing childhood tuberculosis diagnosis in low-income countries with high tuberculosis incidence: Experiences and perceptions from health care workers in Sub-Saharan Africa and South-East Asia. PLOS Glob Public Health. 2023 Oct 11;3(10):e0001525. doi: 10.1371/journal.pgph.0001525. eCollection 2023. PubMed 37819919 ↗

Individual participant data

Plan to share: No

08

Registry details

Key details

Study ID
NCT04038632
Lead sponsor
Institut National de la Santé Et de la Recherche Médicale, France
Collaborators
UNITAID
Responsible party
Sponsor
First posted
Jul 31, 2019
Start date
Mar 7, 2020
Primary completion
Mar 31, 2022
Completion
Mar 31, 2022
Last update
Mar 26, 2025

Study contacts

Olivier Marcy, PhD
principal investigator · University of Bordeaux
Maryline Bonnet, PhD
principal investigator · Institut de Recherche pour le Developpement
Eric Wobudeya, PhD
principal investigator · MU-JHU Care Ltd

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion